We have analyzed the incidence of hemorrhagic complications in 807 patients undergoing a n allogeneic hemopoietic stem cell transplant (HSCT) between 1991 and 2001 in our Unit. Median age was 35 years (16-66) and the donor was an HLA identical sibling (n=570) , a family mismatched member (m=74) or an unrelated donor (n=163). At least one hemorrhage was recorded in 238 patients (29%), 23% vs 45% for HLA identical sibling and alternative donors (p<0.0001). The proportion of patients with bleeding episodes was significantly higher in the presence of acute GvHD grade III-IV (55%) as compared to grade II (31%) and grade 0 -I (23%)(p<0.0001). It was comparable in patients receiving bone marrow grafts (24%) or peripheral blood grafts (18%)(p=0.2). The average duration of the episode was 6 days (range 1-90) and occurred as a hemorrhagic cystitis in 38 patients , ad a gut bleeding in 26 and in other sites in 174. Patients with hemorrhages spent significantly more days in Hospital (median 54 days) as compared to patients without bleeding (median 42 days, p<0.0001) and had significantly higher transplant mortality (35% vs 26%, p=0.009). The impact on TRM was particularly significant in patients with or without gut bleeding (63% vs 28%,p=0.0001). We conclude that hemorrhages are a frequent complication of allogeneic HSCT and correlate with acute GvHD. The significant impact on the duration of Hospital admission and on transplant mortality, warrants prospective clinical trials, testing the efficacy of recombinant human activated coagulation factor VII.
Solid Tumors
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The EBMT Solid Tumors Working Party (STWP) Registry: 2001 report
T. Demirer (Ankara, TR)
By November 2001, the EBMT has included 19086 patients with solid tumors, two thirds (66%) being female; mean age is 32.54 years +18.30. To date, 5037 patients received marrow, 13905 PBSC and 144 received both. Overall toxic death rate in 1991 was 6%, while in 2000 it was reduced to less than 2% (all ages, all diseases) for all patients. Probably this may be due not only to the universal use of PBPC in recent years, but to a better patients' selection and p ossibly, to an increased knowledge of the procedure. Our working party has performed a survey to determine the future strategies in order to design new studies in patients with high-risk primary and metastatic breast cancer with a questionnaire which was sent to transplant centers in the Europe. Survey analysis will be announced during Montreux Meeting. For limited SCLC and stage III-IV ovarian carcinoma, long-term disease free-survival is approaching 20% and 40%, but only the results of the ongoing EBMT studies (random-ICE and OVCAT) will be able to clearly assess the role of autotransplantation over standard chemotherapy. A new phase-I study was activated this year to investigate the efficacy of allogeneic mini-transplant in patients with refractory solid tumors. Also, a new phase-III study for platinum sensitive relapse epithelial ovarian cancer will be activated in the beginning of 2002. Detailed analyses are being carried out by several EBMT centers, with the aim to hopefully provide possible prognostic factors as to patients treated with high-dose chemotherapy for solid tumors.
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High-dose mitoxantrone (Mito) + melphalan (Mel) with autologous peripheral stem cells (Apsc) infusion in metastatic breast cancer (Mbc) patients M. Martino, F. Morabito, G. Console, G. Messina, G. Irrera, M. Fujo, M. Nardi, V. Pavone, G. Filippelli, G. Cicero, S. Molica, S. Palazzo, R. Giannicola, P. Iacopino (Reggio Calabria, Bari, Paola, Rossano, Catanzaro, Cosenza, I) High-dose chemotherapy (HDC) with APSC rescue has been most frequently used in breast cancer (BC), even it has not yet proven its worth in randomised controlled trials. Anthracyclines are among the most active agents in advanced BC. MITO demonstrated a different toxicity profile when compared to doxorubicin. Haematological and extrahaematological toxicity of MITO containing regimens prior APSC was evaluated in 37 MBC patients, median age 38 years (range 33-54). Autograft was the final part of a HDC, including a induction phase with 3 courses of conventional c hemotherapy with Epirubicin 120 mg/m2 and Cyclophosfamide (CTX) 600 mg/m2 and a first course of myeloablative regimens including CTX 600 mg/m2, Thiotepa 500 mg/m2 and Carboplatin 800 mg/m2. Autograft phase included: 1) HD MITO given at 60 mg/m2 on day -4; 2) HD MEL given at 160 mg/m2 on day -2; 3) APSC infusion with a median of 8.5 x 106 CD34+/kg (range 3-16) on day 0; 4) G-CSF 5 mcg/kg on day +3. The median number of days in hospital was 23.5 (range 15-35). The median duration of severe neutropenia and thrombocytopenia was 9 (range 8-13) and 16 (range 9-29) days, respectively. The median number of units of erythrocytes and platelets transfused was 4.5 (0-11) and 5 (1-9), respectively. 24.3% patients did not develop fever during severe neutropenia. Of the remaining, 75.7% developed fever for a median of 3 (1-8) days (FUO 53.7%, Microbiologically Documented 25%, CVC-related 17.8%, Clinically Documented 3.5%, according to EORTC criteria). No systemic fungal infection was documented and there were no infectious deaths. Mucositis was observed in 81.5% of cases (WHO grade 3-4 in 26.3%). No acute and late cardiac toxicity was observed and left ventricular ejection fraction didn't show any difference during follow-up. Only one patient died because of transplant-related cause (cerebral thromboembolic disease). At a median follow-up of 28 mo. (range 5-80), median PFS and OS were 18 and 34 mo, respectively. Furthermore, 32% of pts were predicted to remain alive and 20% progression-free at 64 mo. We conclude that a conditioning regimen with HD of MITO + MEL fits well within the HDC program. It implies good tolerability and no cardio toxicity.
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High-dose chemotherapy with autologous peripheral blood progenitor cell transplantetion in patients with germ-cell tumors J. Nepomucká, L. Boublíková, Z. Donátová Z, J. Charvát, J. Kalanin, M. Greplová, M. Bártová, J. Abrahámová (Prague, CZ) Autologous peripheral blood progenitor cell rescue was provided in our center, from January 1998 to September 2001, to 22 patients with relapsed or refractory germ-cell tumors. Median age was 27 years and tumor markers were elevated -HCG in 6 and AFP in 5 patients at the time of high dose chemotherapy. Stem cell mobilization was performed after the 3rd cycle of VeIP in combination with G-CSF. The amount of CD 34+cell/kg b.w. was between 2.0 -10.3x106. High-dose conditioning regimen CARBOPEC (carboplatin 1600 -2 200 mg/m2 , etoposide 1800mg/m2 , cyclophosphamide 6400 mg/m2 ) was used. The treatment was well tolerated without transplant -related mortality. Engraftment was rapid, recovery of hematopoiesis in neutrofils over 1.0x109/l and platelets over 50x109/l was reached an average on days +10 and +13 respectively, using filgrastim 5 ug/ kg beginning the day +6. Using WHO criteria , hematological toxicity was grade IV, non-hematological toxicity of the therapy was predominantly of grade II .The follow-up period is from 3 to 41 month. At present, 12 (55% )out of 22 patients are alive ( 10 pts are in CR, 2 pts are in SD ), 10 (45%) pts died. Among 12 surviving pts two pts after autologous transplantation had retroperitoneal lymphadenectomy, five pts received 3rd line chemotherapy with Paclitaxel and Gemcitabin for relapse or persistence of the disease. Patients are reevaluated every 4 months during the first 2 years. In conclusion, high-dose chemotherapy with autologous PBPC rescue in patients with advanced germ-cell tumors is feasible and promising method of treatment in this group of patients. Results of multicentric randomized EBMT study IT 94 are needed to exactly evaluate the role of this method in the therapy of patients with germ-cell tumors.
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Genomic imbalances predict outcome in patients with highrisk breast cancer treated with high-dose chemotherapy and autologous stem cell transplantation J. Climent, J.A. Martinez-Climent, D. Blesa, I. Marugan, R. Saez, D. Sanchez, M.J. Garcia, P. Azagra, A. Lluch, J. Garcia-Conde (Valencia, E) Breast cancer development and progression is associated with the accumulation of genetic aberrations that have been proposed to determine tumour phenotypes and clinical evolution of patients (pts). We used comparative genomic hybridization (CGH) to perform a genome-wide screening of DNA copy number variation on 34 frozen and paraffin tumors from pts with high risk breast cancer (HRBC), stages II-III (10 or more lymph nodes affected), treated with high dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). With a median follow-up time of 74 months, 15 pts (44%) have relapsed. Using CGH, a total of 383 genomic imbalances was found (median per tumor: 11, range 2-24), including chromosomal gains/amplifications (median: 4) involving 1q (59%), 17q (38%), 16p (35%), 8q (35 %), and 20q (32%), and losses (median: 6) involving 9p (41%), 18q (41%), 11q (38%), 8p (38%), 18p (38%) and 17p (32%). In univariate analysis there was not a correlation between the number of genomic imbalances and the outcome of pts. However pts with 4 or more genomic losses had a shorter disease free survival (DFS) than those with <4 (p=0.03). Pts with gain/amplification of 17q12 affecting the HER2-neu locus (8 cases) had a longer DFS (p=0.02), whereas those with genomic loss of 18p (13 cases) had higher probability of relapse (p=0.003). Other characteristics of pts such as age, menopausal status, number of lymph nodes affected, tumor size, EP receptors and histologic grade were not associated with differences in DFS. These data suggest that the pattern of genomic imbalances may represent a novel marker for predicting the response to therapy in patients with HRBC.
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Combined surgery, sequential double high-dose chemotherapy with autologous peripheral stem cell transplantation and intrathecal radiopeptide brachytherapy for relapsed medulloblastoma of the cauda
M. Sidler, P. Avoledo, A. Gratwohl, .A Merlo, T. Kühne (Basel, CH)
We report a single case of a now 13-year old boy with a medulloblastoma (Initial stage: Chang T3B). After craniotomy and incomplete tumor resection the boy was treated with chemo-and radiotherapy according to a German protocol. Two years after completion of therapy the boy presented with acute urinary retention. Spinal MRI showed a subarachnoid space metastasis (L5-S4).
Since upfront surgery and additional external radiotherapy did not represent an option a sequential double highdose chemotherapy (HDC) followed by autologous peripheral stem cell transplantation (aPBSCT) was performed. Conditioning regimen of course # 1 consisted of thiotepa and etoposide and of course # 2 of cyclophosphamide and melphalan. Time interval between courses # 1 and # 2 was 16 weeks. A leukocyte count of > 1,0 x 109/L was achieved at day 11 for both cycles. HDC was well tolerated. Between the first and second aPBSCT, the remaining tumor was removed by a laminoplastia (L4-S4). Subsequently the treatment was completed by 4 courses of brachytherapy intrathecally injecting Yttrium-90 labelled modified octreotide (DOTATOC). Medulloblastomas are known to highly express somatostatin receptors. Today, 1 ½ years after completing therapy, the boy is still in complete remission. The most compromising deficit remains the neurological bladder dysfunction with the need of a permanent external drainage. In conclusion this case illustrates the potential of a combined approach in individual complex situations such as relapsed medulloblastoma. The poor prognosis of relapsed braintumors in children allows the search for new treatment modalities. Further clinical trials are necessary to establish timing, intensity and indication of HDC with aPBSCT in relapsed medulloblastoma. Intrathecal brachytherapy using radiolabelled peptidic vectors might represent an additional therapeutic option for relapsed medulloblastomas.
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Outcome of children with solid tumors treated with G-or GM-CSF after high-dose chemotherapy (HDC) and autologous stem cell support (SCS)
U. Gross-Wieltsch, M. Morgan, J. Onneken, S. Legien, M. Schumm, P. Lang, J. Treuner, E. Koscielniak (Stuttgart, Tuebingen, D) G-and GM-CSF are used after HDC and SCS to accelerate neutrophil recovery after HDC. There is increasing evidence that G-CSF in contrast to GM-CSF may negatively affect autologous antitumor immunity after HDC by modulating the balance between Th1 and Th2 cells in favor of Th2. We retrospectively analyzed the data o f patients who underwent autologous stem cell transplantation (SCT) as consolidation therapy and received G-CSF or GM-CSF for accelerating hematopoietic recovery. From 07/89 until 07/01 a total of 67 pts (median age 8,9y) underwent autologous SCT, 34 pts received G-CSF and 33 pts GM-CSF. 12 pts (7 G -CSF/5 GM-CSF) received a double transplant, thus resulting in 79 procedures (41 G-CSF/38 GM-CSF). G-CSF (10 microg/kg) or GM-CSF (250 microg/m²) were given as continuous infusion starting on day +1 (3 G-CSF/23 GM-CSF) from 07/89 until 02/94 and subsequently on day +4 (31 G-CSF/10 GM-CSF). The stem cell source was BM in 3/34 procedures with G-CSF and 23/38 procedures with GM-CSF and PBSC in 38/41 procedures with G-CSF and 15/38 procedures with GM-CSF. Diagnosis consisted of rhabdomyosarcoma (RMS) in 21 pts (10 G-CSF/11 GM-CSF), other soft tissue sarcoma in 12 pts (7 G-CSF/5 GM-CSF), neuroblastoma in 24 pts (12 G-CSF/12 GM-CSF), nephroblastoma in 2 pts (2 G-CSF/0 GM-CSF), germ cell tumor in 1 pt (1 G-CSF/0 GM-CSF), brain tumor in 2 pts (1 G-CSF/1 GM-CSF) and lymphoma in 5 pts (1 G-CSF/4 GM-CSF). 25 pts treated with G-CSF and 27 pts treated with GM-CSF had primary metastatic disease, 9 pts receiving G -CSF and 6 pts receiving GM-CSF had relapsed. 20/34 pts (59%) in the G-CSF group were in CR or VGPR before HDC compared to 26/33 pts (78%) receiving GM-CSF. The median follow up for patients who are still alive was 3,5y (0, (4) (5) (6) 8) in the G-CSF and 4,8y (0,2-12,3) in the GM-CSF group. Relapse or progression rate was 19/34 pts (56%) with G-CSF and 18/33 (55%) with GM-CSF. 15 pts with G-CSF and 14 pts with GM-CSF died due to tumor progression. 19 pts with G-CSF and 19 pts with GM-CSF are still alive. There was 1 second malignancy (osteosarcoma) in the pts with G-CSF in the irradiated site of the primary tumor (RMS). Time to relapse or progression was 0,7y (0,2-3,3) in the pts with G-CSF and 1,3y (0,2-9,9) in pts with GM-CSF. There was no difference in relapse or progression rate in both groups despite the higher proportion of patients in CR or VGPR and the longer time to progression in the GM-CSF treated patients.
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P708 Long-term hematologic recovery following high-dose chemotherapy with autologous peripheral stem cell transplantation (PSCT) or autologous bone marrow transplantation in children with solid tumors G. Deb, A. Landolfo, A. Castellano, I. Ilari, L. De Sio, P. Fidani, A. Jenkner, R. Cozza, A. Lanti, G. Milano, F. Zinno, G. Isacchi, A. Donfrancesco (Rome, I) Objective: BMT from autologous sources has been employed to reconstitute the bone marrow following chemo-radiotherapyconditioning regimens for several years. We performed PBSC collection safely on an outpatient basis. Rescue with PBSC after myeloablative therapy results in a significantly reduced neutropenic period. Patients: Since May 1989 we performed leukapheresis in 132 pts with solid tumors using a Baxter CS-3000 Plus. Patient age ranged from 6 months to 19 years, weight from 6 to 65 kg. 363 PBSC collections were performed with an average of 2 collections per pt. 98 of 132 pts (neuroblastoma 29, Wilms'T. 14, Ewing S. 13, CNS 15, PNET 9, others 18) were subsequently given the thawed product; 5/98 pts had a double transplant. The treatment regimen at 1st transplant consisted of Etoposide 200 mg/m2 days 1, 2 and 3, Thiotepa 250 mg/m2 days 1, 2 and 3, Cytoxan 60 mg/kg days 4 and 5 (ETC). Results: Median recovery time defined equal or greater than 500 PMNs and 50.000 PLTs/mm3 was 16.5 days (range 12-22 days) for PMNs and 19 days (range 8-25 days) for PLTs. Nine pts received PBSC support after submyeloablative therapy; median time of recovery in this patient group was 6.5 days (range 5-13 days) to PMNs and 10 days (range 8-15 days) for PLTs. The introduction of CSF allowed for a significantly shorter recovery time for PMNs. Both G-CSF and GM-CSF were given at 5 mcg/kg each. PMNs greater than 1.000/mm3 and PLTs greater than 50.000/mm3 occurred after 12.5 days (range 5-15 days) and 19 days (range 13-25 days) respectively. 5/98 pts underwent two BMT with a different treatment regimen. To reduce the number of procedures we monitored th CD 34+ count, collecting PBSC when count was above 20 cell/mcL. Up to date 44 (45%) pts are in CR, 8 (8%) are AWD and 46 (47%) DOD. Conclutions: The results of this experience suggest that PBSC can be successfully collected in small children and can be used to reconstitute the bone marrow after myeloablative therapy. The ETC regimen is well tolerated and efficacious in producing prolonged event free survival in high-risk patients.
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Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes (CTL) for the treatment of patients with EBV-positive relapsed nasopharingeal carcinoma P. Comoli, P. Pedrazzoli, A. Nocera, M. Labirio, F. Del Galdo, S. Basso, R. Schiavo, A. Tagliamacco, O. Carminati, R. De Palma, S. Siena, F. Locatelli, R. Maccario (Pavia, Milan, Genoa, Naples, I) Nasopharyngeal carcinoma (NPC) is an EBV-related epithelial neoplasm. Currently, the elective form of treatment for NPC is radiotherapy, alone or combined with chemotherapy, which cures a high percentage of cases presenting with early stage tumor. However, as the prognosis of patients with advanced stage disease remains poor, there is a need to develop additional forms of treatment. It has recently been shown that infusion of EBVspecific CTLs expanded in vitro can safely and effectively control EBV-positive posttransplant lymphoproliferative disease. NPC cells are EBV antigen-positive, and therefore they could also be suitable targets for specific immunotherapeutic treatment. Having been shown that EBV-specific T cell immunity can be significantly reduced in NPC patients compared with that in healthy virus carriers, we explored the feasibility of developing salvage therapy of NPC by an adoptive immunotherapy approach employing HLAidentical family donors as the source of PBMCs to induce and expand EBV-specific CTLs. Our pilot clinical study has concerned patients with advanced stage NPC, for whom HLA-identical donor CTLs were expanded. Immunophenotyping showed that CTLs were on average 90% CD3+, 70% CD8+, 20% CD4+ and contained 10% cells that were CD3+/CD8+/CD56+ and 15% cells of NK phenotype. EBV specificity of the CTL lines was indicated by the strong lysis observed against autologous EBV-LCL, with little or no reactivity against HLA-mismatched targets. In addition, donor CTLs showed a HLA class I-restricted lysis of patients' tumor cells. One of the patients received 4 weekly doses of EBVspecific T cell lines. CTL transfer was well tolerated, and a TC scan performed after the last infusion showed a partial reduction of the intracranial portion of the tumor mass. A tumor biopsy was also performed, and immunocytology analysis demonstrated a marked increase of CD8+ lymphocyte infiltrate in comparison to a pre-infusion sample. Studies are in progress to determine the origin of the lymphocyte infiltrate. Preliminary data obtained in this patient indicate that EBV-specific CTLs can be used safely, are able to exert specific killing of autologous tumor cells in vitro, and have antitumor effect in vivo. Further studies on a larger cohort of patients are required to assess the respective role of donor or autologous EBV-specific CTLs in the control of EBV-positive NPC, and the possibility to implement the clinical results by employing LMP-2 specific CTLs.
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Transplantation of a megadose of full-haplotype mismatched hematopoietic stem cells (HSCT) as a treatment of metastatic relapse of Ewing sarcoma -Report from the Committee on High Risk Sarcoma of the Cooperative Soft Tissue Sarcoma Study (CWS)
E. Koscielniak, T. Klingebiel, U. Gross-Wieltsch, J. Treuner, P. Lang, P. Bader, D. Niethammer, R. Handgretinger (Stuttgart, Frankfurt, Tuebingen, D; Memphis, USA)
The prognosis for patients (pts) with bone and/or bone marrow (B/BM) metastases of soft tissue sarcoma (STS) remains very poor. The 5 yrs EFS of pts registered in the CWS Studies 81-96 was < 5%. Pts with metastatic STS who relapsed had no chance of being cured. Immune reconstitution after HDC is very poor with prolonged CD4 depletion. We h ypothesize that the immune system may play a role in the control of the residual sarcoma cells. Therefore we initiated a prospective phase II study on HSCT from mismatched related donors as a consolidation therapy for pts with B/BM metastases of STS. The c onditioning consisted of busulfan, (4mg/kg/dayx3), thiotepa (10mg/m²/day), cyclophosphamid (50mg/kg/day x 4), fludarabine (30mg/m²/day x 2) and orthoclone (day -4 till + 13). No posttransplant immunosuppression was given. Mobilized peripheral CD34+ cells were selected with CliniMACS device. We report on a 13 year old girl with a disseminated Ewing sarcoma (thorax wall, lung and B/BM) diagnosed in April 1998. The patient was treated according to the CWS-96 Study with 6 drugs combination (CEVAIE) + local irradiation + tandem HDC untill Mai 1999. In Nov. 1999 a tumor relapse was diagnosed (thorax wall, verterbra and skull). We decided to treat the patient on the protocol for haploidentical HSCT. Before conditioning, two 10 days courses of low dose oral therapy of trofosfamid and idarubicin were administered. Cryopreserved cells from the mother were reinfused on day 0 (CD34 8x10E6 /kg and CD3 4835/kg). Additional retransfusions of fresh donor cells were given on days +4 and +5 (CD34 11,1x10E6/kg and CD3 5163/kg). On day +9 the leucocytes were 1600/µl and a chimerism analysis revealed complete donor type. During the posttransplant period a slow regression of the measurable metastatic sites in the skull, vertebra and thorax wall was observed. The patient is alive, tumor progression free, 21 months after HSCT . We conclude that: 1. Tumor regression was initially due to myeloablative conditioning but further regression was possibly due to the graft vs. tumor effect 2. myeloablative conditioning could be advantageous in young patients when tumors are still chemosensitive as a means of reducing the tumor Objectives: To assess efficiency and toxicity for children older than 3 years with high grade brain tumors treated with the SJMB 3/97 protocol (whole craniospinal irradiation with concomitant vincristine and 4 cycles of submyeloablative chemotherapycyclophosphamide, cisplatin, vincristin with PBSC rescue). Methods: Between 1999 and 2001, 18 children (11 boys and 7 girls) were treated with a SJMB 3/97 protocol. Median age at the time of diagnosis was 9,6 years (range 5,0 and 17,7). Diagnoses included medulloblastoma (7), anaplastic astrocytoma (5), high grade ependymoma (3) and PNET (3). Primary tumor was localized in the fourth ventricle (10), supratentorial area (5), thalamus (2) and hemisphere of the cerebellum (1). One child had dissemination at the time of diagnosis. Complete tumor resection was performed in 8 pts, biopsy or subtotal removal of the tumor (residual tumor greater than 1,5 cm2) was performed in 10 pts. Amplification of c-myc was detected in 13 pts., amplification of Nmyc in 4 pts. DNA aneuploidy was found in 6 pts. Results: After surgery all children were irradiated on the craniospinal axis with boost on the primary tumor with concomitant vincristine. After radiotherapy 9 patient were in complete remission, 6 pts in partial remission, 3 pts. experienced disease progression. After chemotherapy were 66% (12/18) pts. in CR, 22% (4/18) pts in PR, 1 pt. in SD, 1 pt. in PD and 1 pt. died of progression. The hemato-and gastrointestinal toxicity were in all patients WHO grade III-IV, neurotoxicity gr. II-III, 1 pt. finished the treatment after 3rd course of chemotherapy due to nefrotoxicity, 1 pt. showed ototoxicity gr. III, 1 pneumotoxicity gr. IV. Conclusions: The crucial prognostic factors in children with embryonal brain tumors are complete resection of the tumor, no evidence of leptomeningeal disease and no evidence of amplification of c-myc oncogene. Initial evaluation show feasibility of this regimen in the treatment of high risk brain tumors with promising results, despite high but manageable toxicity. Further evaluation is necessary.
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Pre-emptive oral vs. I.V. ganciclovir therapy against cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation (Hsct) in patients with solid tumor L. Barkholt, I. Lewensohn-Fuchs, P. Hentschke, L. Stahle, A. Helldén, O. Ringdén (Stockholm, S) Objective: Does the pre-emptive oral ganciclovir (GCV) therapy prevent cytomegalovirus (CMV) disease in patients with solid organ carcinoma after nonmyeloablative HSCT? Methods: In total 17 patients, 6 with colorectal (C1-6), 10 with renal (R1-10) adenocarcinoma and 1 with cholangiocarcinoma (L1), all with metastases, underwent HSCT 1999-2001. The donors were HLA-identical siblings for all but 6 patients. Conditioning included Fludarabine 30 mg/m2 for 3 days, using sibling donors or 5 days using unrelated donors followed by 2 Gy total body irradiation. Antithymoglobulin 4 mg/kg was added to patients with unrelated donor. Immunosuppression was by mycophenolate mofetil and cyclosporine. All patients but one, and 11 donors were CMV seropositive. CMV DNA was monitored weekly by quantitative PCR (Taqman); <10 copies/200.000 PBL defined as positive. Patients, positive for CMV DNA, were randomized to a pre-emptive therapy using either oral GCV (500mgx3 for 5 weeks) or I.V. GCV 5mg/kg/dx2 for 2 weeks plus 5mg/kg/d 5 days/week for 3 weeks. GCV concentrations were monitored weekly. Results: 10/17 (59%) patients developed CMV DNAemia, 2 patients with CMV syndrome, within the first month after HSCT. Five more patients developed CMV DNAemia between months 2 and 5. Nine of the 15 CMV DNA+ patients were administrated oral and 5 patients I.V. GCV. Two oral GCV cases were converted to I.V. therapy due to increasing CMV DNA load and/or clinical CMV syndrome. Both of them died with CMV DNAemia in tumor progress. Additional 3 patients (2 with initially oral and 1 with I.V. therapy) received another and successful oral course due to asymptomatic reinfection within 3 months. The peak CMV DNA load was 570 copies (median 35). The median GCV through levels were 2.6 mikromol/L (range 1.0-4.6) and 1.8 mikromol/L (range 0.7-7.5) in oral and I.V groups, respectively. The median peak I.V. GCV level was 16.4 mikromol/L (range 8.0-23.6). Dose reduction was performed in 3 patients, 2 with oral and 1 with I.V. GCV, due to nephrotoxicity. In addition, 1 patient needed hemodialysis for acute renal failure and confusion with a GCV concentration of 50.9 mikromol/L. Conclusion: CMV DNAemia with moderate CMV load was common in spite of the nonmyeloablative conditioning prior to HSCT. No tissue invasive CMV disease developed. Two of 9 patients with oral pre-emptive GCV were converted to I.V. therapy. GCV concentrations were comparable in oral and I.V. treated patients.
Additional abstracts to this topic
Allogeneic hematopoietic stem cell transplantation after dose-reduced conditioning induces remissions in recurrent ovarian cancer -a report of two cases.
F. Kroschinsky, M. Hanel, C. Rollig, T. Wassa, U. Platzbecker, C. Thiede, G. Ehninger, H. Schmidt, M. Bornhauser (Dresden, Hameln, D) Stem cell supported high-dose chemotherapy (HDT) seems as a promising approach in patients with advanced or recurrent epithelial ovarian cancer. Nevertheless relapses occur after autografting in a substantial number of patients. Further treatment has palliative intention in most cases. Although the effect in ovarian cancer is controversial, allogeneic hematopoietic stem cell transplantation (HSCT) is offered to selected patients with suitable HLA-matched donors. We report two patients who underwent allogeneic HSCT for recurrent epithelial ovarian cancer after sequential HDT. Patient 1 (56 years) was diagnosed FIGO stage III in 1997. Surgical debulking was followed by adjuvant chemotherapy (taxol/carboplatin). In 1999 a first peritoneal relapse could be treated successfully with taxol/cyclophosphamid, whereas two retroperitoneal bulk tumors (about 5 cm in diameter each) detected in 2000 were refractory against sequential HDT (carboplatin/taxol/melphalan) as well as alternative salvage treatment with topotecan. Patient 2 (32 years) underwent surgery and adjuvant chemotherapy for FIGO stage III disease in 1991. Consecutive metastases at vaginal stump, chest wall and retroperitoneal lymph nodes were treated by surgical exstirpation, radiation and chemotherapy including taxanes, platin and topotecan. Further disease progression with left infraclavicular soft tissue metastases, inguinal and iliacal lymph node involvement had to be detected in 2000. Sequential HDT (carboplatin/ topotecan/ treosulfan) induced only short tumor regression. Dose-reduced preparative regimen included busulfan 4 mg/kg orally d -6 and -5, and intravenous fludarabin 30 mg/m² d -6 until -2. G-CSF mobilized peripheral blood stem cells from HLAidentical unrelated (pt 1) or family (pt 2) donor were given on day 0 (pt 1: 11x106, pt 2: 6x106 CD34 cells/kg). GVHD-prophylaxis was cyclosprin A and mycophenolate. Hematological toxicity and mucositis were mild, complete donor chimerism could be detected by STR-PCR on day + 13 in both patients. 12 (pt 1) and 10 (pt 2) months after allogeneic HSCT both patients are alive and well. Pt 1 requires CSA and steroid treatment due to chronic GVHD of the skin (extensive disease), whereas pt 2 lacks any symptoms of GVHD. While tumor response in pt 1 meets the criteria of stable disease, there is a nearly complete remission in pt 2. We conclude that there could be graft-versus-tumor effect in epithelial ovarian cancer. Further evaluation is warranted.
Significance of P-glycoprotein expression in childhood malignant tumors
H. Kucerova, D. Sumerauer, E. Drahokoupilova, M. Piskova, J. Bedrnicek, T. Eckschlager (Prague, CZ) P-glycoprotein (PGP) is a protein involved in efflux of various compounds. Its overexpression in cancer cells decreases intracellular drug concentrations, and thus, confers a multidrug resistance phenotype. Quantitative and functional analysis of PGP is important in determining resistance and therapeutic response. The pretreatment expression of PGP is a prognostic sign of the failure of therapy in many different cancers. We present the results of PGP expression examination in 91 tumor tissue samples obtained from children treated for different malignant tumors. The correlation between the level of PGP expression and tumor histology, clinical outcome, use of therapy, relapse rate and metastatic disease was made. Patient ages ranged from 2 months to 22 years. Samples were analyzed by flow cytometry and Khi2 test was applied. The highest levels of PGP expression were frequently found in the group of soft tissue sarcomas, neuroblastomas, and Ewing family of tumors (p<0,05). Soft tissue sarcomas, neuroblastomas, and hepatoblastomas cells have shown significantly more frequent PGP expression (p<0,05). Brain tumors and nefroblastomas have shown significantly less frequent expression of PGP (p<0,05). In soft tissue sarcomas, we found a nonsignificant increased PGP expression in patients with relapse after or during chemotherapy (N.S., p<0,1). In patients with metastatic disease PGP overexpression was observed in soft tissue sarcomas and neuroblastomas (p<0,05). We found a significant PGP overexpression in soft tissue sarcomas, neuroblastomas and hepatoblastomas. A significant increased PGP expression we proved in patients with soft tissue sarcomas and neuroblastomas with metastatic disease. In brain tumors and nephroblastomas we found significantly less frequent expression of PGP. PGP positive tumor cells were detected more frequently in disseminated disease. There was no significant difference between the tumors examined before the chemotherapy administration and the tumors influenced by the chemotherapy. Our results show that PGP positive phenotype is associated with a metastatic disease especially in soft tissue sarcomas and neuroblastomas. In those tumors PGP expression is frequently seen in recurrence and PGP presence in patients before chemotherapy may be a sign of low response to chemotherapy. We verify that flow cytometry is useful method for PGP detection not only in leukemias but also in solid tumors including brain and bone tumors.
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Mobilazion of peripheral blood stem cells (PBSCs) with chemotherapy and granulocyte-colony stimulating factor (G-CSF): A randomized evaluation of different doses of G-CSF T. Demirer, M. Ayli, M. Ozcan, N. Gunel, R. Haznedar, M. Dagly, T. Fen, Y. Genc, S. Dincer, O. Aslan, G. Gürman, G. Ozet, N. Konuk, O. Ylhan, H. Koc, H. Akan (Ankara, TR) Objective: To date, there is no randomized study comparing different doses of G -CSF following mobilization chemotherapy (MC). Therefore, in this study the effect of different doses of G-CSF following MC on the yields of CD34+ PBSCs were evaluated in patients with hematologic malignancies and solid tumors. Methods: Fifty patients were randomized to receive G-CSF 8 (n = 25) versus 16 (n = 25) ug/kg/day following one of these mobilization regimens: cyclophosphamide (CY) and etoposide; CY and epirubicine; or CY and paclitaxel. Results: The median number of CD34+ cells collected after 8 ug/kg/day of G -CSF was 2.36x106/kg (range 0.21-7.80) as compared to 7.99 (range 2.76-14.89) after 16 ug/kg/day (P<0.001). Among patients randomized to 8 v 16 ug/kg, all (100%) achieved > 4.0 x 106 CD34+ cells/kg and less aphereses were required to achieve > 2.5x106 CD34+ cells/kg after the higher dose (P<0.001). Twenty of 25 (80%) patients in the low dose and 23 of 25 (92%) in the high dose G-CSF arm underwent high dose chemotherapy and autologous stem cell transplantation. Median days of WBC engraftment in patients mobilized with 8 ug/kg and 16 ug/kg of G-CSF were 12 and 9 , respectively (P< 0.001). But there was no difference between 2 groups regarding the other parameters of peritransplant morbidity such as days of platelet engraftment (P=0.10), RBC (P = 0.56) and platelet transfusions (P=0.22), days of TPN requirement (P=0.84), days of fever (P=0.93), and days of antibiotics (P=0.77). Conclusion: These data showed that higher doses of G -CSF following a MC were associated with a clear dose response effect based on the collected cell yields. Based on these results 8 ug/kg/day is as effective as 16 ug/kg/day except for a rapid neutrophil engraftment in the high dose arm. Therefore, in the routine clinical practice, despite some advantage in the use of higher doses of G-CSF, lower doses may be used for PBSC collections following chemotherapy based mobilization regimens in this cost-conscious era.
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Stem cell mobilization by G-CSF in solid and hematological malignancies -Single daily dose better than split dose in obese patients F. Arpaci, B. Ozturk, A. Ozet, S. Komurcu, M. Beyzadeoglu, K. Oysul, S. Ataergin, I. Yilmaz, A. Pekel, A. Sengul, A. Yalcin (Ankara, TR) In the past, different results were reported for single daily and two divided daily G-CSF doses in stem cell collection where no study exists examining the effect of body mass index(BMI) on mobilization. Collected CD34(+) cell numbers were compared in 86 patients with solid and hematological malignancies receiving either single daily 14 mcg/kg/day G -CSF (filgrastim) as group I(n=36) or divided daily two G-CSF doses 2X7 mcg/kg/day as group II (n=50). Both groups were subdivided into a and b groups according to their BMI as group a (BMI < 25 kg/m2) and group b (BMI >25 kg/m2). Two groups were similar in terms of age, gender and disease characteristics. All the patients have received G-CSF as a single or two divided doses subcutaneously and apheresis has been done on the 5th day, 4 hours after the last dose. No significant CD34(+) cell number difference between groups Ia and Ib, groups IIa and IIb, groups Ia and IIa were found. On the other hand, the median ratio and the number of CD34(+) cells in group
